RXRX heads into Q3 earnings with key collaboration milestones, advancing clinical programs and upcoming pipeline updates that ...

Recursion Pharmaceuticals Inc. RXRX shares are trending on Friday. Shares of the Utah-based clinical-stage biotechnology company edged 0.24% higher to $4.17 after the bell on Thursday, following a ...

President and Chief Executive Officer - Najat Khan ...

Recursion (Nasdaq: RXRX), a leading clinical-stage company pioneering AI-enabled drug discovery and development, today announced that its Board of Directors has appointed Fred Hassan as Chair, ...

The article mentions how symbolic recursion can destabilize identity and it’s how the true self emerges but it’s kinda vague on the details or the how and I just want to know how much of this is true?

Recursion Pharmaceuticals (RXRX) remains a 'Sell' as its ~$1.8B valuation is unsupported by clinical or commercial progress. REC-4881's efficacy in FAP is unremarkable versus Celebrex, with uncertain ...

Recursion said it expects to launch its first registrational trial in the second half of this year for its lead candidate REC-4881 based on talks with the FDA, after the oral familial adenomatous ...

Shares of Recursion Pharmaceuticals (NASDAQ: RXRX) were sinking 8.2% lower as of 10:57 a.m. ET on Monday. The clinical-stage biotech company, which is a pioneer in using artificial intelligence (AI) ...

Chris Gibson, PhD, Recursion’s co-founder and CEO, discusses exclusively with GEN Edge his company’s ambitious plans to develop 100 pipeline candidates in roughly a decade, the savings in money and ...

Recursion Q3 2026 earnings: clinical wins for REC-4881 and REC-1245, Sanofi progress, and cash runway to 2029.

The overall stock market decline likely weighed on Recursion's shares. CNBC host Jim Cramer's recent hesitation about the biotech stock could also be causing angst for investors. Part of the reason ...